OVID THERAPEUTICS INC. - COMMON STOCK

Ovid Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights

16 Aug 2021 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

08 Jul 2021 15:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

07 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

04 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

26 May 2021 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

13 May 2021 15:05:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

12 May 2021 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board

20 Apr 2021 07:00:02 By Nasdaq GlobeNewswire

OVID Provides Update on OV101 Program and the Prioritization of its Resources

19 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of Soticlestat

30 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021

15 Mar 2021 07:00:02 By Nasdaq GlobeNewswire